SEC Form 4 · accession 0001193125-26-403101
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Chess
Director
Period of report
Sep 23, 2026
Accepted (ET)
Sep 25, 2026 · 8:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Sep 23, 2026 | A | 2,000 | $0.00 | A | 19,019 | D | |
| Common StockF3,F4 | holding | — | — | — | 140 | I | by daughter | |
| Common StockF3,F4 | holding | — | — | — | 140 | I | by son | |
| Common stockF3,F4 | holding | — | — | — | 140 | I | by daughter |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF5 | $57.66 | Sep 23, 2026 | A | 4,000 | A | — | Sep 22, 2034 | Common Stock | 4,000 | 4,000 | D |
Explanation of responses
- F1Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
- F2This RSU award vests in full, one year following September 23, 2026.
- F3On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
- F4The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
- F5This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.